Singh R, Singh A, Singh AK. Human pregnancy outcomes after early glucagon-like peptide-1 receptor agonist exposure: A scoping review. World J Diabetes 2026; 17(10): 124799 [DOI: 10.4239/wjd.124799]
Corresponding Author of This Article
Ritu Singh, MD, Department of Reproductive Medicine, Horizon Multispecialty Hospital, P-34, C.I.T Road, Kolkata 700014, West Bengal, India. drritusingh73@gmail.com
Research Domain of This Article
Obstetrics & Gynecology
Article-Type of This Article
research-article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Singh R, Singh A, Singh AK. Human pregnancy outcomes after early glucagon-like peptide-1 receptor agonist exposure: A scoping review. World J Diabetes 2026; 17(10): 124799 [DOI: 10.4239/wjd.124799]
World J Diabetes. Oct 15, 2026; 17(10): 124799 Published online Oct 15, 2026. doi: 10.4239/wjd.124799
Human pregnancy outcomes after early glucagon-like peptide-1 receptor agonist exposure: A scoping review
Ritu Singh, Akriti Singh, Awadhesh Kumar Singh
Ritu Singh, Department of Reproductive Medicine, Horizon Multispecialty Hospital, Kolkata 700014, West Bengal, India
Ritu Singh, Department of Gynecology & Obstetrics, G. D Hospital & Diabetes Institute, Kolkata 700013, West Bengal, India
Akriti Singh, Department of Medicine, KPC Medical College & Hospital, Kolkata 700032, West Bengal, India
Awadhesh Kumar Singh, Department of Diabetes & Endocrinology, G. D Hospital & Diabetes Institute, Kolkata 700013, West Bengal, India
Co-first authors: Ritu Singh and Awadhesh Kumar Singh.
Author contributions: Singh R conceptualized the study and wrote the first draft; Singh A and Singh AK conducted the literature review and revised the draft; and all authors agreed to submit the final manuscript. Singh R and Singh AK contributed equally to this study as co-first authors.
AI contribution statement: AI tools, specifically ChatGPT 5.6, were used to assist with the formatting of some figures. No AI tool was used to generate research data, interpret results, or formulate conclusions. All AI-assisted content was critically reviewed and revised by the authors, who take full responsibility for the accuracy, originality, and integrity of the manuscript.
Conflict-of-interest statement: All authors declare no competing interest.
PRISMA 2009 Checklist statement: The Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews documents are attached as Supplementary material.
Corresponding author: Ritu Singh, MD, Department of Reproductive Medicine, Horizon Multispecialty Hospital, P-34, C.I.T Road, Kolkata 700014, West Bengal, India. drritusingh73@gmail.com
Received: June 24, 2026 Revised: July 17, 2026 Accepted: August 28, 2026 Published online: October 15, 2026 Processing time: 110 Days and 11.8 Hours
Core Tip
Core Tip: This scoping review maps the full human evidence spectrum on glucagon-like peptide-1 receptor agonist exposure before conception and during early pregnancy, from case reports to meta-analyses. The most important finding is cautiously reassuring: no consistent overall signal of major congenital malformations has emerged after inadvertent early exposure. However, pregnancy loss, termination, hypertensive disorders, preterm birth, fetal growth, and renal/genitourinary signals remain uncertain and highly confounded. Clinicians should reassure women after accidental exposure, stop glucagon-like peptide-1 receptor agonists once pregnancy is recognized, and avoid planned or continued use during pregnancy until stronger prospective evidence is available.
